Product Information
HYSINGLA ER 60 MG TABLET is a brand product labeled by Purdue Pharma LP, priced at $36.1746 per EA under NDC 59011027460. Its NADAC has been published 585 times since Jul 22, 2015.
FDA first approved this application on Nov 20, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
60 mg/1
Manufacturer
Purdue Pharma LPNDC
59011027460
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCODONE BITARTRATEApproval Type
New Drug (NDA)
FDA Application
NDA206627FDA Approved
11/20/2014
TE Code
AB
On Market Since
1/15/2015
Pharmacological Classes
Price Statistics
The NADAC for HYSINGLA ER 60 MG TABLET has been published 585 times since Jul 22, 2015, and over the history we have for it it has risen 109.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $36.1746 per EA |
|---|---|
| All-time high | $36.3036 (Aug 12, 2026) |
| All-time low | $17.2466 (Jul 22, 2015) |
| 52-week high | $36.3036 |
| 52-week low | $33.3528 |
| Median price | $27.0901 |
| Average price | $26.5747 |
| Largest weekly change | +9.5% (Jan 10, 2018) |
| Weeks tracked | 585 |
| Tracking since | Jul 22, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the hydrocodone bitartrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Purdue Pharma LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
hydrocodone bitartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYSINGLA ER 60 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HYSINGLA ER 60 MG TABLET, manufactured by Purdue Pharma LP, is $36.1746 per EA (NDC 59011027460), effective Sep 30, 2026.
How has the price of HYSINGLA ER 60 MG TABLET changed over time?
Over the history we have for it, the NADAC for HYSINGLA ER 60 MG TABLET has risen 109.7%. It has been tracked across 585 weekly CMS publications since Jul 22, 2015.
What are the highest and lowest recorded NADAC prices for HYSINGLA ER 60 MG TABLET?
Since Jul 22, 2015, the NADAC for HYSINGLA ER 60 MG TABLET has ranged from a low of $17.2466 (Jul 22, 2015) to a high of $36.3036 (Aug 12, 2026), with a median of $27.0901 per EA.
Are there cheaper alternatives to HYSINGLA ER 60 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of HYSINGLA ER 60 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HYSINGLA ER 60 MG TABLET?
HYSINGLA ER 60 MG TABLET (NDC 59011027460) is labeled by Purdue Pharma LP, and CMS classifies it as a brand product.